NCT06943235 Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC)
| NCT ID | NCT06943235 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Fudan University |
| Condition | Limited Stage Small Cell Lung Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-04-25 |
| Primary Completion | 2027-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 60 participants in total. It began in 2025-04-25 with a primary completion date of 2027-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
ADRIATIC study explored the benefits of immune maintenance therapy after LS-SCLC radiotherapy and chemotherapy. In the presence of immunotherapy, is it necessary to increase the dosage of radiotherapy and can it further improve the efficacy? This study aims to explore the efficacy and safety of simultaneous integrated boost hyperfractionation radiotherapy combined with probiotics and Adalberg monoclonal antibody consolidation therapy for small cell lung cancer.
Eligibility Criteria
Inclusion Criteria: 1. Sign written informed consent before implementing any experimental procedures; 2. Age range: 18-80 years old; 3. Pathological diagnosis of small cell lung cancer; 4. Limited stage; 5. ECOG PS 0-1； 6. Receive ≤ 2 rounds of chemotherapy or chemotherapy plus immunotherapy; 7. Expected survival time\>3 months; Exclusion Criteria: 1. Progress after 2 induction treatments; 2. Severe emphysema, interstitial changes in the lungs, COPD patients; 3. Resting blood oxygen\<93; 4. Have a history of other malignant tumors and have received chemotherapy in the past 3 years; 5. History of chest radiotherapy;
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06943235 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Limited Stage Small Cell Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06943235 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06943235 currently recruiting?
Yes, NCT06943235 is actively recruiting participants. Contact the research team at wenxingfan@126.com for enrollment information.
Where is the NCT06943235 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06943235 clinical trial?
NCT06943235 is sponsored by Fudan University. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.